US Declines to Pressure Decrease Worth on Most cancers Drug Xtandi
WASHINGTON (Reuters) – The U.S. authorities is not going to pressure Pfizer Inc and Astellas Pharma Inc to decrease the worth of their prostate most cancers drug Xtandi utilizing its emergency “march-in” authority, the Nationwide Institutes of Well being (NIH) stated on Tuesday.
March-in rights, which have by no means been used earlier than, permit the federal government to grant further licenses to 3rd events for merchandise developed utilizing federal funds if the unique patent holder doesn’t make them accessible to the general public on cheap phrases.
Xtandi’s wholesale value is between $160,000-$180,000 per affected person a yr.
Affected person group the Union for Inexpensive Most cancers Therapy first filed a petition calling on the NIH to make use of its authority to decrease the drug’s value in March 2016.
The NIH stated in a letter made public on Tuesday that its analyses in response to the petition discovered the prostate most cancers remedy was extensively accessible.
“NIH doesn’t imagine that use of the march-in authority could be an efficient technique of reducing the worth of the drug,” the letter stated.
Pfizer and Astellas weren’t instantly accessible for remark. The businesses are anticipated to have mixed income from Xtandi of greater than $2 billion this calendar yr, in line with information from Refinitiv.
March-in rights had been launched as a safeguard within the Bayh-Dole Act of 1980 which permits the inventors to retain possession of innovations developed with public funds and maintain patents, as is the case with Xtandi.
Progressive lawmakers within the Democratic Get together have been calling on President Joe Biden’s administration to make use of its march-in authority to decrease drug costs.
The Division of Well being and Human Providers additionally denied a petition for a congressional listening to regarding potential value gouging on the drug, which was developed with authorities funding, Consultant Lloyd Doggett, the highest Democrat on the Home’s Methods and Means Well being Subcommittee, stated in an announcement.
The U.S. Division of Well being and Human Providers (HHS) and the Division of Commerce (DOC) stated on Tuesday they’d undertake a evaluate of the federal government’s march-in authority as specified by the Bayh-Dole Act.
(Reporting by Julie Steenhuysen in Chicago and Ahmed Aboulenein in Washington; Enhancing by Caroline Humer and Lincoln Feast.)
Copyright 2023 Thomson Reuters.